摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dimethylcarbamic acid 3-(6-aminopyridin-2-ylmethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester | 946126-31-4

中文名称
——
中文别名
——
英文名称
dimethylcarbamic acid 3-(6-aminopyridin-2-ylmethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester
英文别名
[3-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-oxochromen-7-yl] N,N-dimethylcarbamate
dimethylcarbamic acid 3-(6-aminopyridin-2-ylmethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester化学式
CAS
946126-31-4
化学式
C19H19N3O4
mdl
——
分子量
353.378
InChiKey
WBHSEIPUNHSUFK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    564.3±50.0 °C(predicted)
  • 密度:
    1.317±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    94.8
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-甲基-2-氧代-1,3-恶唑烷-3-磺酰胺dimethylcarbamic acid 3-(6-aminopyridin-2-ylmethyl)-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester三乙胺 作用下, 以 乙腈 为溶剂, 反应 12.0h, 以23.3 mg的产率得到dimethylcarbamic acid 4-methyl-3-{6-(methylaminosulfonyl)aminopyridin-2-ylmethyl}-2-oxo-2H-1-benzopyran-7-yl ester
    参考文献:
    名称:
    Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
    摘要:
    Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 1 la and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impact after nitrogen substitution on interactions between a derivative and its on- and off-target proteins (Raf/MEK, CYPs, and hERG channel) was also detected, most of them contributing to weaker interactions. After identifying the positions that kept inhibitory activity on HCT116 cell growth and Raf/MEK, compound I (CH5126766/RO5126766) was selected as a clinical compound. A phase I clinical trial is ongoing for solid cancers.
    DOI:
    10.1021/ml400379x
  • 作为产物:
    参考文献:
    名称:
    Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning
    摘要:
    Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 1 la and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impact after nitrogen substitution on interactions between a derivative and its on- and off-target proteins (Raf/MEK, CYPs, and hERG channel) was also detected, most of them contributing to weaker interactions. After identifying the positions that kept inhibitory activity on HCT116 cell growth and Raf/MEK, compound I (CH5126766/RO5126766) was selected as a clinical compound. A phase I clinical trial is ongoing for solid cancers.
    DOI:
    10.1021/ml400379x
点击查看最新优质反应信息

文献信息

  • Novel Coumarin Derivative Having Antitumor Activity
    申请人:Iikura Hitoshi
    公开号:US20110092700A1
    公开(公告)日:2011-04-21
    The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.
    本发明提供一种由下式(1)或其药学上可接受的盐所表示的化合物:其中,X选自杂环芳基等;Y1和Y2选自—N═等;Y3和Y4选自—CH═等;A选自磺酰胺等;R1选自氢等;R2选自C1-6烷基等。该化合物或盐具有足够高的抗肿瘤活性,并可用于治疗细胞增殖性疾病,特别是癌症。本发明还提供一种含有该化合物或盐作为活性成分的制药组合物。
  • p27 Protein Inducer
    申请人:Sakai Toshiyuki
    公开号:US20110009398A1
    公开(公告)日:2011-01-13
    The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from —N═ etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from —CH 2 — etc., and R 2 is selected from C 1-6 alkyl etc.
    本发明提供了一种p27蛋白诱导剂,其包含以下通式(11)所表示的化合物或其药学上可接受的盐作为活性成分:其中G1,G2,G3和G8各自独立地选择自—N═等,环G6选择自双价芳基等,A选择自氨基等,G4选择自氧等,G5选择自氧等,G7选择自—CH2—等,R2选择自C1-6烷基等。
  • p27 PROTEIN INDUCER
    申请人:Chugai Seiyaku Kabushiki Kaisha
    公开号:EP2172198B1
    公开(公告)日:2014-04-16
  • NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP1982982B1
    公开(公告)日:2012-09-26
  • EP1982982A1
    申请人:——
    公开号:EP1982982A1
    公开(公告)日:2008-10-22
查看更多